 |
85 Diseases |  |
26 Trials |
|
26 Trials |  |
4609 News |  |
| «12...345678910111213...5758» |
- cemdisiran (ALN-CC5) / Alnylam, Regeneron, pozelimab (REGN3918) / Regeneron
Trial completion, Trial completion date, Combination therapy: Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy (clinicaltrials.gov) - Jun 13, 2023
P2, N=6, Completed, Sponsor: Regeneron Pharmaceuticals
Active, not recruiting --> Completed | Trial completion date: May 2024 --> May 2023
- | Soliris (eculizumab) / AstraZeneca
Journal: Starting eculizumab as rescue therapy in refractory myasthenic crisis. (Pubmed Central) - Jun 12, 2023
The use of eculizumab in myasthenic crisis is still investigational, but this case report suggests that it may be a promising treatment option for patients with severe clinical condition. Ongoing clinical trials will be needed to further evaluate the safety and efficacy of eculizumab in myasthenic crisis.
- | Soliris (eculizumab) / AstraZeneca
Journal: Efficacy and Safety of Eculizumab in Pediatric Patients Affected by Shiga Toxin-Related Hemolytic and Uremic Syndrome: A Randomized, Placebo-Controlled Trial. (Pubmed Central) - Jun 12, 2023
Ongoing clinical trials will be needed to further evaluate the safety and efficacy of eculizumab in myasthenic crisis. In pediatric STEC-HUS patients, eculizumab treatment does not appear to be associated with improved renal outcome during acute phase of the disease but may reduce long-term kidney sequelae.
- || Review, Journal: An update on the biologics for the treatment of antiphospholipid syndrome. (Pubmed Central) - Jun 9, 2023
This review focuses on the recent advancements in the pathogenesis of APS and explores the potential of targeted treatments, including eculizumab, rituximab, belimumab, daratumumab, obinutuzumab, and anti-TNF-? antibodies, for APS management.
- ||||| Soliris (eculizumab) / AstraZeneca, crovalimab (RG6107) / Roche
Clinical, Adverse events: Lots of new #PNH data at the #EHA2023 oral #BMFsm session! @AustinKulasekar presented data from the COMMODORE1 study looking at patients with tx #PNH on C5 inhibitors; received crovalimab versus eculizumab. Disease controlled on both arms. No increase in side effects. 1/3 👇 (Twitter) - Jun 9, 2023
- | Empaveli (pegcetacoplan SC) / Apellis, SOBI
Journal: Complement Inhibitors in the Management of Complement-Mediated Hemolytic Uremic Syndrome and Paroxysmal Nocturnal Hemoglobinuria. (Pubmed Central) - Jun 8, 2023
Complement inhibitor therapies have changed the treatment landscape for CM-HUS and PNH. With a significant emphasis on patient QOL, novel therapies continue to emerge and require an in-depth review of their appropriate use and efficacy in these rare disorders.
- ||| Soliris (eculizumab) / AstraZeneca
Long shot for the #MedTwitter verse - is anyone familiar with research on eculizumab for the tx of typical HUS in adults?!🩸🩸 This topic in the literature seems focused on kiddos @AaronGoodman33 @ASCO @JCO_ASCO #heme (Twitter) - Jun 5, 2023
- |||| Soliris (eculizumab) / AstraZeneca
New P3 trial: Soliris: Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China (clinicaltrials.gov) - Jun 2, 2023
P3, N=25, Not yet recruiting, Sponsor: Alexion
- Soliris (eculizumab) / AstraZeneca
CD59 deficiency: a very rare, potentially curable form of infection induced neuromotor regression (Foyer 3B, 3rd Floor) - May 29, 2023 - Abstract #EPNS2023EPNS_684;
Currently one year after start eculizumab the patient did not suffer from neuromotor regression anymore. Moreover, her muscle force and mobility ameliorated.
- || Empaveli (pegcetacoplan SC) / Apellis, SOBI
Review, Journal: Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations. (Pubmed Central) - May 29, 2023
Moreover, her muscle force and mobility ameliorated. Implementation of these recommendations uniformly across healthcare institutions will promote the best use of complement inhibition in managing PNH, and has the potential to positively impact patient outcomes in Central Europe and worldwide.
- | Soliris (eculizumab) / AstraZeneca
Journal: Germline C1GALT1C1 mutation causes a multisystem chaperonopathy. (Pubmed Central) - May 26, 2023
AKI in the male patients proved fully responsive to treatment with the complement inhibitor Eculizumab...Interestingly, all four affected individuals have high levels of galactose-deficient IgA1 in sera. These results demonstrate that the A20D-Cosmc mutation defines a novel O-glycan chaperonopathy and causes the altered O-glycosylation status in these patients.
- | Soliris (eculizumab) / AstraZeneca
Journal: Delayed Hematological Remission Predicts Poor Renal Outcome in Children with Atypical Hemolytic Uremic Syndrome. (Pubmed Central) - May 26, 2023
Eculizumab is the standard of care for children with aHUS...Delayed initiation of plasma therapy and longer time to achieve hematological remission are associated with lower eGFR on follow-up. Long-term monitoring of hypertension and proteinuria is needed in these children.
- || Soliris (eculizumab) / AstraZeneca
Review, Journal: Prognostic Significance of the Coagulation and Complement Systems in Critical COVID-19 Infection. (Pubmed Central) - May 26, 2023
Among these drugs, low molecular weight heparin enoxaparin, factor Xa inhibitor apixaban, and complement C5 inhibitor eculizumab have been commonly used in patients with COVID-19. Our overall experience might help us in the future to tackle any such conditions.
- | Soliris (eculizumab) / AstraZeneca
Journal: Eculizumab treatment alters the proteometabolome beyond the inhibiton of complement. (Pubmed Central) - May 25, 2023
Our overall experience might help us in the future to tackle any such conditions. For this purpose, we studied a cohort of MG patients treated with either eculizumab (n = 10) or azathioprine (n = 10) as well as treatment-na
- ||| Soliris (eculizumab) / AstraZeneca
New trial: Soliris: Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China (clinicaltrials.gov) - May 25, 2023
P=N/A, N=25, Not yet recruiting, Sponsor: Alexion
- | Soliris (eculizumab) / AstraZeneca
Journal: The nailfold dermoscopy findings of patients with atypical haemolytic uremic syndrome. (Pubmed Central) - May 24, 2023
For this purpose, we studied a cohort of MG patients treated with either eculizumab (n = 10) or azathioprine (n = 10) as well as treatment-na A dermoscopy can be used as a screening tool for disease activity in patients with aHUS.
- | Soliris (eculizumab) / AstraZeneca
Journal: Complement inhibitors for kidney disease. (Pubmed Central) - May 23, 2023
In this review, we survey the evidence on using complement inhibition from the earliest, small-scale studies focusing on C5-targeting agents to more recent, large, multi-center, randomized trials utilizing complement blockade higher up in the complement pathway at the level of C3. We conclude by examining where the field of complement targeting therapy may be headed in light of these studies.
- | Journal: Therapeutic Strategies for Neuromyelitis Optica (Pubmed Central) - May 21, 2023
Recently, biologic agents such as eculizumab, satralizumab, inebilizumab, and rituximab have been approved for use in Japan. Although side effects caused by steroid therapy have been issues for patients in the past, active use of the newly approved biologics is expected to help patients avoid the adverse effects of steroids and improve their qualities of life.
- || Retrospective data, Review, Journal: Efficacy of Innovative Therapies in Myasthenia Gravis: Systematic Review, Meta-Analysis and Network Meta-Analysis. (Pubmed Central) - May 19, 2023
With the limitations of this meta-analysis, including efficacy time-points, FcRn treatments showed a short-term higher effect on the QMG. Real-life studies with long-term measurements are needed to confirm our results.
- Soliris (eculizumab) / AstraZeneca
Eculizumab use in the postpartum period for the treatment of pregnancy associated atypical hemolytic uremic syndrome: retrospective cohort study (Room:Exhibition) - May 18, 2023 - Abstract #ISTH2023ISTH_1465;
- Soliris (eculizumab) / AstraZeneca
A case report of quinine-induced thrombotic microangiopathy treated with eculizumab (Room:Exhibition) - May 18, 2023 - Abstract #ISTH2023ISTH_1061;
- | Soliris (eculizumab) / AstraZeneca
Journal: Eculizumab for the treatment of glycine receptor antibody associated stiff-person syndrome. (Pubmed Central) - May 18, 2023
Real-life studies with long-term measurements are needed to confirm our results. No abstract available
- | Soliris (eculizumab) / AstraZeneca
New P1 trial: Comparative PK, Safety, Tolerability, Immunogenicity, and PD Profile Study of TUR03 and Soliris in Healthy Participants (clinicaltrials.gov) - May 18, 2023
P1, N=120, Recruiting, Sponsor: Turgut Ardika PTY LTD
- || Empaveli (pegcetacoplan SC) / Apellis, SOBI
NICE, Review, Journal: Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. (Pubmed Central) - May 17, 2023
3 months. Pegcetacoplan was the first technology recommended by NICE via the low ICER FTA process.
- | Soliris (eculizumab) / AstraZeneca, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: A series of patients with refractory myasthenia gravis. (Pubmed Central) - May 15, 2023
Pegcetacoplan was the first technology recommended by NICE via the low ICER FTA process. The percentage of patients with refractory MG in our series (13%) is similar to those reported in previous studies; these patients were often women and presented early onset, severe forms of onset, and repeated relapses requiring hospital admission during follow-up.
- Soliris (eculizumab) / AstraZeneca
PROSPECTIVE SELF-CONTROL ANALYSIS OF GLUCOCORTICOID MAINTENANCE THERAPY FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA () - May 12, 2023 - Abstract #EHA2023EHA_3296;
Long-term glucocorticoid maintenance therapy for PNH was not recommend. Paroxysmal nocturnal hemoglobinuria (PNH), Hemolysis, Therapy, Anemia
- Soliris (eculizumab) / AstraZeneca
SEVERE HEMOLYSIS OF PNH PATIENTS ASSOCIATED WITH OMICRON INFECTION IN CHINA () - May 12, 2023 - Abstract #EHA2023EHA_3294;
Compared with hemolytic episodes in the past, the hemolysis induced by Omicron is more intense. Eculizumab could effectively improve the of hemolysis induced by Omicron infection in patients with PNH.
- Empaveli (pegcetacoplan SC) / Apellis, SOBI
THE COMPLETE STUDY: A SINGLE ARM, MULTICENTER OBSERVATIONAL STUDY TO EVALUATE EFFECTIVENESS OF PEGCETACOPLAN UNDER REAL WORLD CONDITIONS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) () - May 12, 2023 - Abstract #EHA2023EHA_3293;
P3
This study aims to describe real-world usage and effectiveness of pegcetacoplan in PNH patients. Paroxysmal nocturnal hemoglobinuria (PNH), Quality of life, Complement, Real world data
- iptacopan (LNP023) / Novartis
APPULSE-PNH: A PHASE IIIB TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SWITCHING TO IPTACOPAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) ON ANTI-C5 THERAPY WITH HEMOGLOBIN >10G/DL () - May 12, 2023 - Abstract #EHA2023EHA_3292;
P3
APPULSE will assess the efficacy and safety of switching to IPTA monotherapy from SoC anti-C5 therapy in PNH pts with Hb ?10 g/dL, a population not included in the Phase III APPLY-PNH trial. PNH, Paroxysmal nocturnal hemoglobinuria (PNH), Clinical trial
- Soliris (eculizumab) / AstraZeneca, Bekemv (eculizumab biosimilar) / Amgen
SENSITIVITY AND SUBGROUP ANALYSES FURTHER SUPPORT CLINICAL SIMILARITY IN EFFICACY BETWEEN ABP 959 AND ECULIZUMAB REFERENCE PRODUCT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) () - May 12, 2023 - Abstract #EHA2023EHA_3288;
The results of this study, along with previously demonstrated analytical, non-clinical, and clinical similarity, validate the robustness of similarity in clinical efficacy and are consistent with the conclusion of no clinically meaningful differences between ABP 959 and eculizumab RP. Paroxysmal nocturnal hemoglobinuria (PNH), PNH
- Promacta (eltrombopag) / Novartis
THE COMBINATION OF ANTI-COMPLEMENT THERAPY AND CYCLOSPORINE +/- ELTROMBOPAG IN PNH IS EFFECTIVE AND SAFE: A REAL-LIFE OBSERVATIONAL STUDY. () - May 12, 2023 - Abstract #EHA2023EHA_3286;
Further prospective trials with a large number of patients are needed to validate these results and elucidate the role of combination treatment with CSA and eltrombopag therapy together with anti C5 agents. Aplastic anemia, Complement, Paroxysmal nocturnal hemoglobinuria (PNH), Cyclosporin A
- Soliris (eculizumab) / AstraZeneca, Ultomiris IV (ravulizumab-cwvz IV) / AstraZeneca
PREVALENCE OF CLINICALLY SIGNIFICANT EXTRAVASCULAR HEMOLYSIS IN STABLE C5 INHIBITOR-TREATED PATIENTS WITH PNH AND ITS ASSOCIATION WITH DISEASE CONTROL, QUALITY OF LIFE AND TREATMENT SATISFACTION () - May 12, 2023 - Abstract #EHA2023EHA_3285;
P3
Background: Complement component 5 inhibitors (C5i) eculizumab and ravulizumab reduce thrombosis and organ damage, and improve survival for patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare hematologic disorder characterized by uncontrolled terminal complement activation. Clinical trial prevalence of csEVH (20.2
- Soliris (eculizumab) / AstraZeneca
PREGNANCY IN PATIENTS WITH APLASTIC ANEMIA () - May 12, 2023 - Abstract #EHA2023EHA_3284;
Clinical trial prevalence of csEVH (20.2 Three patients with severe AA (SAA) at baseline received combined IST (ATG+cyclosporine A), of them the complete remission (CR) was available in 1 patient, and partial remission (PR) in 2 patients with a combination of AA and paroxysmal nocturnal hemoglobinuria (AA/PNH)...Therefore, eculizumab was prescribed to both patients according to newly emerging indications
- Empaveli (pegcetacoplan SC) / Apellis, SOBI
EXPOSURE-RESPONSE ANALYSES OF PEGCETACOPLAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA () - May 12, 2023 - Abstract #EHA2023EHA_3283;
Pegcetacoplan 1080 mg SC twice weekly dosing was supported by the models as effective in patients with PNH who are naive to complement inhibitors and in those switching from C5 inhibitors to pegcetacoplan. Hemoglobin, Complement, Paroxysmal nocturnal hemoglobinuria (PNH), Anemia
- Empaveli (pegcetacoplan SC) / Apellis, SOBI
POPULATION PHARMACOKINETICS OF PEGCETACOPLAN IN HEALTHY SUBJECTS AND PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA () - May 12, 2023 - Abstract #EHA2023EHA_3282;
Predictions from the model further suggest that no adjustment to initial dosing is needed for the specific populations represented by the intrinsic or extrinsic factors evaluated in this analysis. Complement, Population, Paroxysmal nocturnal hemoglobinuria (PNH), Pharmacokinetic
- SB12 (eculizumab biosimilar) / AffaMed Therap, Samsung, Soliris (eculizumab) / AstraZeneca
POPULATION PHARMACOKINETIC/PHARMACODYNAMIC/EFFICACY MODELING OF SB12 (PROPOSED ECULIZUMAB BIOSIMILAR) AND REFERENCE ECULIZUMAB () - May 12, 2023 - Abstract #EHA2023EHA_3280;
The population modeling showed PK/PD/efficacy similarities between SB12 and ECU in pooled population of healthy subjects and PNH patients, supporting the totality of evidence on biosimilarity for SB12. Clinical data, Monoclonal antibody, Paroxysmal nocturnal hemoglobinuria (PNH), Phase III
- Soliris (eculizumab) / AstraZeneca, Ultomiris IV (ravulizumab-cwvz IV) / AstraZeneca
REAL-WORLD CLINICAL PRACTICES IN TREATMENT DISCONTINUATION WITH COMPLEMENT C5 INHIBITORS FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME: A GLOBAL SURVEY OF HEALTHCARE PROFESSIONALS (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1977;
Our findings indicate that there is some commonality among HCPs regarding key factors whenconsidering C5i discontinuation, including kidney function and comorbidities, and their monitoring practice. HCPs need more clinical data and guidance on C5i discontinuation and monitoring, to help with the development of robust personalized treatment strategies for patients with aHUS.
- Soliris (eculizumab) / AstraZeneca, Ultomiris IV (ravulizumab-cwvz IV) / AstraZeneca
HOSPITALIZATION IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A RETROSPECTIVE ANALYSIS OF OBSERVATIONAL STUDY DATA FROM THE UNITED STATES (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1054;
Despite well-established efficacy of C5i, we found that residual anemia and hemolysis still affect many treated PNH pts. Our data have limited statistical power and longer follow-up is needed.
- cemdisiran (ALN-CC5) / Alnylam, Regeneron, Soliris (eculizumab) / AstraZeneca, pozelimab (REGN3918) / Regeneron
A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF COMBINATION POZELIMAB AND CEMDISIRAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO SWITCH FROM ECULIZUMAB (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1053;
P2
Findings support the ongoing development of pozelimab and cemdisiran combination therapy. PNH, Clinical trial, Hemolysis, Hemolytic anemia
- iptacopan (LNP023) / Novartis, tesidolumab (LFG316) / Novartis, MorphoSys
EFFICACY AND SAFETY OF SWITCHING TO IPTACOPAN (IPTA) MONOTHERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATED WITH THE ANTI-C5 MONOCLONAL ANTIBODY (MAB) TESIDOLUMAB (TESI) (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1052;
P2, P3
TESI was effective in improving Hb and PNH type III RBCs, with further increases in Hb seenwhen switching to IPTA. Improvements in reticulocytes and bilirubin were seen when pts switched to IPTA, suggesting that IPTA controlled both IVH and EVH.
- danicopan (ALXN2040) / AstraZeneca, Soliris (eculizumab) / AstraZeneca, Ultomiris IV (ravulizumab-cwvz IV) / AstraZeneca
PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND CLINICALLY SIGNIFICANT EXTRAVASCULAR HEMOLYSIS ON RAVULIZUMAB/ECULIZUMAB SHOWED HEMOGLOBIN RESPONSE SUPERIORITY WITH ADD-ON DANICOPAN VS PLACEBO (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1049;
P3
Danicopan as add-on to Rav/Ecu significantly improves Hgb and reduces need for transfusion by addressing cs-EVH while maintaining control of IVH with a favorable benefit risk profile. Paroxysmal nocturnal hemoglobinuria (PNH), Phase III
- Empaveli (pegcetacoplan SC) / Apellis, SOBI
EVALUATION OF PEGCETACOPLAN TREATMENT SUCCESS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WITH AND WITHOUT BONE MARROW FAILURE: A MOVE TOWARDS INDIVIDUALIZED PATIENT TREATMENT (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1046;
P3
Nevertheless, patients with BMF syndromes showed benefit in hematologic and clinical outcomes in response to PEG treatment. Treatment success may best be evaluated against individually set treatment targets.
- Ultomiris IV (ravulizumab-cwvz IV) / AstraZeneca
LONG-TERM RAVULIZUMAB TREATMENT IN COMPLEMENT INHIBITOR-EXPERIENCED PATIENTS WITH PNH PROVIDES DURABLE CONTROL OF INTRAVASCULAR HEMOLYSIS WITH LOW INCIDENCE OF MAJOR ADVERSE VASCULAR EVENTS AND DEATH. (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1043;
P3
Treatment success may best be evaluated against individually set treatment targets. Study 302 (NCT03056040) is a phase 3 randomized open-label active?controlled non-inferiority multicenter study comparing the efficacy and safety of ravulizumab with eculizumab in clinically stable adult patients with PNH who had received eculizumab treatment for ?6 months and had lactate dehydrogenase (LDH) levels ?1.5
- pozelimab (REGN3918) / Regeneron
LONG-TERM EFFICACY AND SAFETY OF POZELIMAB MONOTHERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1042;
P2, P3
Pozelimab was also generally well tolerated. Pozelimab may be a potentially effective long-term treatment for patients with PNH.
- Empaveli (pegcetacoplan SC) / Apellis, SOBI
THROMBOSIS AND MENINGOCOCCAL INFECTION RATES IN PEGCETACOPLAN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IN THE CLINICAL TRIAL AND POST-MARKETING SETTINGS (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1041;
P2, P3
Proximal complement inhibition with pegcetacoplan may notincrease the meningococcal infection risk compared with terminal complement inhibitors. Continued follow-up is required.
- Soliris (eculizumab) / AstraZeneca, Ultomiris IV (ravulizumab-cwvz IV) / AstraZeneca
CLINICAL, HUMANISTIC, AND ECONOMIC BURDEN IN PATIENTS WITH PNH RECEIVING C5 INHIBITION TREATMENT ACROSS UK, GERMANY, AND FRANCE. INSIGHTS FROM THE COMMODORE BURDEN OF ILLNESS STUDY (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1036;
Further, this is one of the first reports of outcomes from the PNH-specific QLQ-AA/PNH-54. The persistent unmet need and disease burden requires alternative treatment options and appropriate support.
- Empaveli (pegcetacoplan SC) / Apellis, SOBI
INCIDENCE RATES OF HEALTHCARE RESOURCE UTILIZATION AND HEMOGLOBIN LEVELS DURING OPERA: A REAL-WORLD STUDY OF PEGCETACOPLAN TREATMENT IN US ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1026;
In this real-world study of US adults with PNH receiving PEG, patients experienced low incidence rates of associated HCRU and a positive trend in Hb levels, after initiating treatment. Hemoglobin, Real world data, Paroxysmal nocturnal hemoglobinuria (PNH), Incidence
- Soliris (eculizumab) / AstraZeneca, crovalimab (RG6107) / Roche
PHASE III RANDOMIZED, MULTICENTER, OPEN-LABEL COMMODORE 1 TRIAL: COMPARISON OF CROVALIMAB VS ECULIZUMAB IN COMPLEMENT INHIBITOR-EXPERIENCED PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) (Illusion) - May 12, 2023 - Abstract #EHA2023EHA_891;
P3
The safety profile of crova in C5i-experienced pts with PNH is consistent with that in C5i-naive pts, except for transient, self-limiting T3H events unique to pts switching between crova and ecu. The COMMODORE 1 data comparing crova vs ecu in C5i-experienced pts support the favorable benefit
- iptacopan (LNP023) / Novartis
ORAL IPTACOPAN MONOTHERAPY INCREASES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE VIA CONTROL OF INTRA- AND EXTRAVASCULAR HEMOLYSIS IN ANTI-C5-TREATED PNH PATIENTS WITH ANEMIA (Illusion) - May 12, 2023 - Abstract #EHA2023EHA_890;
P3
Oral IPTA monotherapy significantly improved Hb levels vs. SoC without the need for RBCTs. By maintaining intravascular hemolysis control and reducing C3 deposition leading to EVH, IPTA monotherapy led to an expected increase in PNH RBC survival to the extent that they formed >90% of the total RBC population.
- Soliris (eculizumab) / AstraZeneca, crovalimab (RG6107) / Roche
THE PHASE III, RANDOMIZED COMMODORE 2 TRIAL: RESULTS FROM A MULTICENTER STUDY OF CROVALIMAB VS ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS NAIVE TO COMPLEMENT INHIBITORS (Illusion) - May 12, 2023 - Abstract #EHA2023EHA_889;
P3
The COMMODORE 2 study demonstrated that crova was non-inferior to ecu in both co-primary efficacy endpoints and had a comparable safety profile. These data highlight the overall favorable benefit